SNRPA is a core component of the U1 small nuclear ribonucleoprotein (snRNP), the spliceosome subunit that recognizes the 5' splice site during pre-mRNA splicing.
The SNRPA gene encodes a protein involved in RNA processing and splicing mechanisms critical for neuronal function and survival.
SNRPA participates in the spliceosome-mediated removal of introns from pre-mRNA. Dysregulation of splicing factors has been implicated in several neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and spinal muscular atrophy (SMA). The spliceosome, a large ribonucleoprotein complex, undergoes dynamic conformational changes during the splicing cycle, and SNRPA contributes to splice site recognition and catalytic steps.
Alterations in RNA splicing are a hallmark of many neurodegenerative disorders. Mutations in genes encoding splicing factors can lead to aberrant splicing patterns that affect neuronal viability. The SNRPA protein is expressed in various brain regions, including the cortex, hippocampus, and spinal cord, where it supports proper RNA metabolism essential for neuronal health.
| Disease | Relationship | Evidence |
|---|---|---|
| Amyotrophic Lateral Sclerosis (ALS) | Dysregulated splicing | Altered expression in ALS motor neurons |
| Frontotemporal Dementia (FTD) | Splicing abnormalities | Found in inclusion bodies in FTD |
| Spinal Muscular Atrophy (SMA) | Spliceosome dysfunction | Part of the SMN complex regulation |
SNRPA is expressed ubiquitously in human tissues, with high expression in:
Targeting splicing modulation represents a therapeutic strategy for neurodegenerative diseases. Small molecule splicing modulators are being developed to restore proper splicing patterns. The SNRPA protein may serve as a biomarker for spliceosome dysfunction in neurodegeneration.